Study to assess safety and efficacy of Inj Sepsivac in patients of Covid-19

Phase 2

• Conditions: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

• Registration Number: CTRI/2020/05/025350
• Lead Sponsor: R D Gardi Medical College

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Patients between the age of 18 â?? 65 years diagnosed to have Covid19 infection confirmed by RTPCR assay,

and

any one or more of the following

1. Either an oxygen saturation of 94% or less while the patient was breathing ambient air or a need for oxygen support

2. Creatinine clearance above 30 ml per minute

3. Serum levels of ALT and AST less than five times the upper limit of the normal range

4. Requirement of vasopressor

Exclusion Criteria

1.Pregnant or nursing female.

2.Patient previously enrolled into similar study.

3.Patient participating or having participated in a clinical trial with another investigational drug within the last 28 days except for investigational drugs against cancer, leukaemia or HIV.

4.Patients not likely to complete the trial as per judgment of the investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified